Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Nov 18, 2008
CONTACT: Revance Therapeutics, Inc. Niquette Hunt Vice President, Marketing & Business Development (510) 742-3400 Newark, Calif. November 18, 2008 — Revance Therapeutics, Inc. (“Revance”) today announced an agreement with Leader Ventures and Horizon Technology Finance that will provide $8 million...
Jul 9, 2009
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. — July 9, 2009 — Revance Therapeutics, Inc. (“Revance”) today announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow’s feet wrinkles, demo...
Jul 28, 2009
CONTACT: Medicis Pharmaceutical Corporation Kara Stancell Executive Director, Investor Relations & Corporate Communications (480) 291-5854 Revance Therapeutics, Inc. Niquette Hunt Senior Vice President, Commercial Development (510) 742-3464 SCOTTSDALE, Ariz. and NEWARK, Calif. – July 2...
Jan 4, 2010
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – January 4, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced the first $25M closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fun...
Oct 22, 2010
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – October 22, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinim toxin type A which is under investig...
Jun 10, 2011
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – June 10, 2011 – Revance Therapeutics, Inc. (“Revance”) today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital (Nov...
Oct 8, 2012
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif.—October 8, 2012 — Revance Therapeutics, Inc. (Revance) today announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation (NYSE:MRX) concerni...
Mar 25, 2013
CONTACT: Revance Therapeutics, Inc. Niquette L. Hunt Senior Vice President, Commercial Development NEWARK, California—March 25, 2013 — Revance Therapeutics, Inc. (Revance) today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President of Corporate Development effect...
Apr 2, 2013
CONTACT: Lauren Silvernail Chief Financial Officer and EVP Corporate Development 510-742-3415 lsilvernail@revance.com NEWARK, California — April 2, 2013 — Revance Therapeutics, Inc. (Revance), a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aestheti...
Feb 5, 2014
NEWARK, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools